IPN60090

IPN60090 is a potent, orally bioavailable, and highly selective small molecule inhibitor of glutaminase 1 (GLS1), also known as the kidney-type glutaminase. GLS1 is a mitochondrial enzyme that catalyzes the conversion of glutamine to glutamate, a key step in cellular energy metabolism and anaplerosis. Inhibition of GLS1 disrupts tumor cell proliferation by limiting their ability to utilize glutamine for growth and survival. IPN60090 was developed with optimized pharmacokinetic and physicochemical properties to achieve high oral exposures and robust target engagement in vivo. It demonstrated strong antitumor activity in preclinical models and entered phase 1 clinical trials for solid tumors, including non-small cell lung cancer (NSCLC) and ovarian cancer. The drug was jointly developed by Ipsen and The University of Texas MD Anderson Cancer Center[1][2][3][5][7].

Other names

IPN 60090IPN60090IPN-60090